|
Agent | Type | Drug targets | Phase | Patient selection | Status | NCI reference | Manufacturer |
|
ARQ 197 | | | | | | | |
Tivantinib (T) T plus sorafenib T plus pazopanib T plus temsirolimus T plus topotecan | Receptor TKI: non-ATP competitive | cMET | I I Ib I I | HCC Solid tumors Solid tumors* Solid tumors Solid tumors | Recruiting Active, not R Recruiting Recruiting Recruiting | NCT01656265 NCT00827177 NCT01468922 NCT01625156 NCT01654965 | Daiichi Sankyo |
|
XL 184 | | | | | | | |
Cabozantinib | Receptor TKI: ATP competitive | cMET, RET, VEGFR1-3, KIT, FLT3, and TIE2 | II II | Solid tumors Solid tumors | Active, not R Recruiting | NCT00940225 NCT01588821 | Exelixis |
|
INC280 | | | | | | | |
Formerly INCB028060 | Receptor TKI: ATP competitive | cMET | I I I | Solid tumors Solid tumors* Solid tumors | Recruiting Recruiting Active, not R | NCT01546428 NCT01324479 NCT01072266 | Novartis Incyte |
|
GSK1363089 | | | | | | | |
Foretinib Formerly XL 880 | Receptor TKI: ATP competitive | cMET, RON, VEGFR1-3, PDGFR, KIT, FLT3, and TIE2 | I/II | HCC | Active, not R | NCT00920192 | GSK |
|
AMG 208 | Receptor TKI: ATP competitive | cMET, VEGFR1-3, RON, and TIE2 | I | Solid tumors | Active, not R | NCT00813384 | Amgen |
|
AMG 337 | Receptor TKI: ATP competitive | cMET | I | Solid tumors | Recruiting | NCT01253707 | Amgen |
|
EMD 1214063 | Receptor TKI: ATP competitive | cMET | I | Solid tumors* | Recruiting | NCT01014936 | EMD Serono |
|
PF-02341066 | | | | | | | |
Crizotinib (Cr) Crizotinib Cr plus pemetrexed or pazopanib | Receptor TKI: ATP competitive | cMET, ALK, and ROS | I I I | Solid tumors* Solid tumors Solid tumors* | Recruiting Recruiting Recruiting | NCT00585195 NCT01576406 NCT01548144 | Pfizer |
|
E7050 | | | | | | | |
E7050 E7050 plus sorafenib | Receptor TKI: ATP competitive | cMET | I I/II | Solid tumors HCC | Recruiting Recruiting | NCT01428141 NCT01271504 | Eisai |
|
MGCD-265 | | | | | | | |
MGCD-265 MGCD-265 plus erlotinib or docetaxel | Receptor TKI: ATP competitive | cMET, RON, VEGFR1-2, PDGFR, KIT, FLT3, and TIE2 | I I/II | Solid tumors Solid tumors | Recruiting Recruiting | NCT00697632 NCT00975767 | MethylGene |
|
SAR125844 | Receptor TKI: ATP competitive | cMET | I I | Solid tumors* Solid tumors* | Recruiting Recruiting | NCT01391533 NCT01657214 | Sanofi |
|
ASLAN002 | | | | | | | |
Formerly BMS777607 | Receptor TKI: ATP competitive | cMET | I | Solid tumors | Recruiting | NCT01721148 | Aslan |
|
AV-299 | | | | | | | |
Ficlatuzumab plus/minus erlotinib Formerly SCH 900105 | Ligand antagonist: monoclonal antibody | HGF | I | Solid tumors | Active, not R | NCT00725634 | AVEO |
|
LY 2875358 | | | | | | | |
LY 2875358 LY 2875358 plus/minus erlotinib | Receptor inhibitor: monoclonal antibody | cMET | I I | Solid tumors Solid tumors | Recruiting Recruiting | NCT01602289 NCT01287546 | Eli Lilly |
|
OPB-31121 | IL-6-induced STAT3 phosphorylation inhibitor | STAT3 | I/II | HCC | Recruiting | NCT01406574 | Otsuka |
|
OPB-51602 | IL-6-induced STAT3 phosphorylation inhibitor | STAT3 | I I | Solid tumors Solid tumors | Active, not R Recruiting | NCT01423903 NCT01184807 | Otsuka |
|